WhiteNest Pharma announces a pivotal moment in the quest for innovative periodontal treatments. Our latest project, focused on the use of lyophilized umbilical cord blood platelet lysate for periodontal regeneration, has been meticulously developed and is now poised for the final stage of regulatory approval from the Spanish Agency for Medicines and Health Products (AEMPS).
Under the expert guidance of Principal Investigator Mariano Sanz Alonso, alongside a distinguished team of researchers, this Phase 1 trial titled “The Use of Lyophilized Umbilical Cord Blood Platelet Lysate in Periodontal Regeneration of Intraosseous Defects: An Open-Label Proof of Principle Study,” has successfully navigated the initial phases of approval. With a protocol rigorously reviewed and endorsed by the Complutense University of Madrid’s ethics committee, our study is set to explore an uncharted territory in dental medicine. The commitment of ten participants will soon bring new insights into periodontal therapy, marking a significant stride towards addressing periodontitis with groundbreaking regenerative techniques.
The forthcoming approval from AEMPS is more than a procedural step; it represents the culmination of collaborative efforts and rigorous planning. This milestone will not only enable the commencement of this trailblazing study but also solidify WhiteNest Pharma’s role at the forefront of regenerative medicine research. Our focus remains on delivering innovative solutions that promise to enhance patient care and treatment outcomes in periodontal disease.
WhiteNest Pharma remains steadfast in our mission to pioneer advances in healthcare. As we await the final nod from AEMPS, our team is prepared to embark on this exciting phase of clinical research, hopeful for the potential benefits it will bring to individuals suffering from periodontal conditions. We are committed to transparency and will continue to provide updates on this important journey.